An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma

Immune-based treatments represent a promising new class of therapy designed to boost the immune system to specifically eradicate malignant cells. Immunotherapy may generate specific anti-tumor immune responses, and dendritic cells (DC), professional antigen-presenting cells, are widely used in experimental cancer immunotherapy. Several reports describe methods for the generation of mature, antigen-pulsed DC for clinical use. Improved quality and standardization are desirable to obtain GMP-compliant protocols. In this study we describe the generation of DC from 31 Glioblastoma (GB) patients starting from their monocytes isolated by immunomagnetic CD14 selection using the CliniMACS® device. Upon differentiation of CD14+ with IL-4 and GM-CSF, DC were induced to maturation with TNF-α, PGE2, IL-1β, and IL-6. Whole tumor lysate was obtained, for the first time, in a closed system using the semi-automated dissociator GentleMACS®. The yield of proteins improved by 130% compared to the manual dissociation method. Interestingly the Mean Fluorescence Intensity for CD83 increased significantly in DC pulsed with “new method” lysate compared to DC pulsed with “classical method” lysate. Our results indicate that immunomagnetic isolation of CD14+ monocytes using the CliniMACS® device and their pulsing with whole tumor lysate proteins is a suitable method for clinical-scale generation of high quality, functional DC under GMP-grade conditions.

[1]  G. Bartsch,et al.  CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer , 1998, The Lancet.

[2]  G. Shankar,et al.  The COSTIM bioassay: a novel potency test for dendritic cells. , 2004, Journal of immunological methods.

[3]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[4]  A. Belldegrun,et al.  Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides , 2000 .

[5]  D. Diaz,et al.  Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients , 2012, Cancer Immunology, Immunotherapy.

[6]  Jonathan K. H. Tan,et al.  Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity , 2005, Journal of leukocyte biology.

[7]  G. Finocchiaro,et al.  Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice , 2006, Neurological research.

[8]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[9]  J. Menten,et al.  Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial , 2012, Cancer Immunology, Immunotherapy.

[10]  Nina Bhardwaj,et al.  Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[11]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[12]  G. Finocchiaro,et al.  Dendritic cell vaccines for cancer stem cells. , 2009, Methods in molecular biology.

[13]  S. Ferrini,et al.  New perspectives in glioma immunotherapy. , 2011, Current pharmaceutical design.

[14]  H. Shinohara,et al.  Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas , 2003, International journal of cancer.

[15]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[16]  G. Ehninger,et al.  Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. , 2003, Journal of hematotherapy & stem cell research.

[17]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[18]  T. Noll,et al.  Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application , 2003, Cytotechnology.

[19]  R. Yamanaka,et al.  Cell- and peptide-based immunotherapeutic approaches for glioma. , 2008, Trends in molecular medicine.

[20]  D. Bigner,et al.  Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[22]  S. Endres,et al.  Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. , 2008, Journal of immunological methods.

[23]  K. Foon,et al.  Type 1‐polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia , 2008, Journal of leukocyte biology.

[24]  R. Steinman,et al.  Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Schuler,et al.  Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. , 1999, Journal of immunological methods.

[26]  L. Liau,et al.  Dendritic cell vaccines for brain tumors. , 2010, Neurosurgery clinics of North America.

[27]  K M Ardeshna,et al.  A Clinically Applicable Method for the ex vivo Generation of Antigen–Presenting Cells from CD34+ Progenitors , 2000, Vox Sanguinis.

[28]  F. Menghi,et al.  Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. , 2006, Cancer research.

[29]  M. Moser,et al.  Depending on their maturation state, splenic dendritic cells induce the differentiation of CD4+ T lymphocytes into memory and/or effector cells in vivo , 2004, European journal of immunology.

[30]  T. Mussack,et al.  Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study , 2011, Cancer Immunology, Immunotherapy.